European glucose monitoring market set to double by 2016
This article was originally published in Clinica
Europe’s continuous glucose monitoring (CGM) market will more than double by 2016, analysts Frost & Sullivan believe. This growth is in response primarily to the increasing demand for an easy-to-use and patient-friendly glucose-monitoring device. The segment will generate revenues totalling $52m in 2016, up from an estimated $23.5m in 2009, according to the report European Market for Continuous Glucose Monitoring, which covers the Benelux countries, France, Germany, Italy, Scandinavia, Spain and the United Kingdom.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.